We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
China ETFs have long been crushed due to regulators’ crackdown on various sectors, mainly the all-important technology space. The stringent COVID-related policies and lockdown as well as a crisis in the debt-laden real estate sector also weighed on the Chinese equities this year.
However, things have been changing for the better. China ETFs that were hit hard earlier in the year started to spring higher. November’s astral rebound in Chinese stocks got another boost this week as plans for a sweeping rescue package to bail out developers sent property stocks rallying. Global X MSCI China Real Estate ETF jumped more than 10% on Monday to reflect the benefit of that package.
Financial regulators issued a 16-point plan to improve the real estate market, with measures that range from addressing developers’ liquidity crisis to loosening down-payment requirements for homebuyers, according to people familiar with the matter.
There has also been easing Covid controls that raised hopes about the turnaround of the economy. Frantic buying amid a fear of missing out on the rally has sent one measure of volatility in the Hang Seng China Enterprises Index to the highest globally, per Bloomberg. The Hang Seng China gauge has now risen about 20% from a recent low on Oct 31, which confirms the definition of a technical bull market.
Overseas investors put a net 16.6 billion yuan ($2.4 billion) into China equities via trading links with Hong Kong on Monday, the biggest purchase since December 2021. That’s on top of a net 14.7 billion yuan they purchased on Friday, per Bloomberg.
“We stay equal-weight on Chinese equities within the global EM framework,” the Morgan Stanley strategists wrote. “We continue to like select exposure to IT, materials and industrials, given their better alignment with top-down policy tailwind,” per Morgan Stanley, as quoted on Bloomberg.
Against this backdrop, below we highlight a few China ETFs that have gained maximum in the past month.
ETFs in Focus
Loncar China BioPharma ETF – Up 27.3% Past Month
The underlying Loncar China BioPharma Index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of pharmaceutical and biotech related industries from China. The fund charges 79 bps in fees.
Global X MSCI China Health Care ETF – Up 22.0%
The underlying MSCI China Health Care 10/50 Index tracks the performance of companies in the health care sector in the MSCI China Index. The fund charges 65 bps in fees.
Global X MSCI China Information Technology ETF – Up 19.2%
The underlying MSCI China Information Technology 10/50 Index tracks the performance of companies in the information technology sector in the MSCI China Index. The fund charges 65 bps in fees.
KraneShares MSCI All China Health Care Index ETF (KURE - Free Report) – Up 17.1%
The underlying MSCI China All Shares Health Care 10/40 Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The fund charges 65 bps in fees.
KraneShares SSE Star Market 50 Index ETF (KSTR - Free Report) – Up 16.6%
The underlying SSE Science and Technology Innovation Board 50 Index comprises of 50 largest companies listed on the SSE Science and Technology Innovation Board as determined by market capitalization and liquidity. The fund charges 88 bps in fees.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
China ETFs Rallying: Top Gainers Past Month
China ETFs have long been crushed due to regulators’ crackdown on various sectors, mainly the all-important technology space. The stringent COVID-related policies and lockdown as well as a crisis in the debt-laden real estate sector also weighed on the Chinese equities this year.
However, things have been changing for the better. China ETFs that were hit hard earlier in the year started to spring higher. November’s astral rebound in Chinese stocks got another boost this week as plans for a sweeping rescue package to bail out developers sent property stocks rallying. Global X MSCI China Real Estate ETF jumped more than 10% on Monday to reflect the benefit of that package.
Financial regulators issued a 16-point plan to improve the real estate market, with measures that range from addressing developers’ liquidity crisis to loosening down-payment requirements for homebuyers, according to people familiar with the matter.
There has also been easing Covid controls that raised hopes about the turnaround of the economy. Frantic buying amid a fear of missing out on the rally has sent one measure of volatility in the Hang Seng China Enterprises Index to the highest globally, per Bloomberg. The Hang Seng China gauge has now risen about 20% from a recent low on Oct 31, which confirms the definition of a technical bull market.
Overseas investors put a net 16.6 billion yuan ($2.4 billion) into China equities via trading links with Hong Kong on Monday, the biggest purchase since December 2021. That’s on top of a net 14.7 billion yuan they purchased on Friday, per Bloomberg.
“We stay equal-weight on Chinese equities within the global EM framework,” the Morgan Stanley strategists wrote. “We continue to like select exposure to IT, materials and industrials, given their better alignment with top-down policy tailwind,” per Morgan Stanley, as quoted on Bloomberg.
Against this backdrop, below we highlight a few China ETFs that have gained maximum in the past month.
ETFs in Focus
Loncar China BioPharma ETF – Up 27.3% Past Month
The underlying Loncar China BioPharma Index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of pharmaceutical and biotech related industries from China. The fund charges 79 bps in fees.
Global X MSCI China Health Care ETF – Up 22.0%
The underlying MSCI China Health Care 10/50 Index tracks the performance of companies in the health care sector in the MSCI China Index. The fund charges 65 bps in fees.
Global X MSCI China Information Technology ETF – Up 19.2%
The underlying MSCI China Information Technology 10/50 Index tracks the performance of companies in the information technology sector in the MSCI China Index. The fund charges 65 bps in fees.
KraneShares MSCI All China Health Care Index ETF (KURE - Free Report) – Up 17.1%
The underlying MSCI China All Shares Health Care 10/40 Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The fund charges 65 bps in fees.
KraneShares SSE Star Market 50 Index ETF (KSTR - Free Report) – Up 16.6%
The underlying SSE Science and Technology Innovation Board 50 Index comprises of 50 largest companies listed on the SSE Science and Technology Innovation Board as determined by market capitalization and liquidity. The fund charges 88 bps in fees.